/** blogpostTitle: Fairchem Organics Q4 FY26: Margin recovery in a weak year, and a reset around utilisation and exports */

Fairchem Organics Q4 FY26: Margin recovery in a weak year, and a reset around utilisation and exports

Fairchem Organics closed FY26 with a mixed print: a weak full year, but a better fourth quarter on margins. In Q4 FY26, revenue from operations was INR 1,169 million (down 3.2% YoY), EBITDA was INR 80 million, and PAT (excluding exceptional items) was INR 37 million. For FY26, revenue from operations declined to INR 4,596 million (down 14.5% YoY), EBITDA fell to INR 216 million, and PAT (excluding exceptional items) was INR 62 million.

Management attributed the FY26 slump largely to weak offtake from the paints industry and an unfavorable pricing environment that reduced volumes and profitability. At the same time, the company highlighted that Q4 FY26 EBITDA margin improved to 6.87% as domestic realizations improved on reduced import pressure. The concall commentary repeatedly tied the quarter’s margin recovery to easing price aggression from Chinese imports, especially in dimer acid.

FY26 performance: volumes fell, margins compressed

The longer trendline shows the stress clearly. EBITDA margins have compressed for three consecutive years, from 10.78% in FY24 to 7.96% in FY25 and 4.70% in FY26. PAT margins have also declined to 1.35% in FY26 from 4.09% in FY25.

The concall added an operating context behind the income statement. FY26 volumes sold were stated at 44,000 tonnes versus 54,000 tonnes in FY25. Management suggested that the company had deliberately produced and sold less during periods of adverse pricing, as selling at unviable prices would have hurt profitability further. This is consistent with management’s recurring emphasis that pricing pressure, rather than plant constraints, was the core issue.

Financial snapshot (as reported)

A second stress point was working capital. The presentation reported a cash conversion cycle of 128 days in FY26 (up from 99 days in FY25 and 76 days in FY24). On the call, the CFO said working capital is expected to remain around 100 to 120 days.

What drove Q4 margin recovery: realizations improved as import pressure eased

The Q4 margin improvement was the most important near-term positive. Management explicitly stated that better price realization in the domestic market, due to lower imports, supported EBITDA margins.

In the concall, management also described that Chinese dumping in dimer acid had reduced since late February, and that realizations improved about 8% to 10%. They did not disclose product-level pricing, but the direction was clear: reduced low-priced imports allowed Fairchem to sell more profitably.

The company also pointed to internal efficiency measures. Management said an energy audit was conducted over the preceding year and that investments in equipment such as pumps, motors and heat exchangers helped reduce energy costs, with further reductions expected.

Revenue mix and market exposure: dimer and linoleic remain meaningful

The company does not provide a formal audited product-segment note in the supplied documents, but management did share headline product contribution data for FY26 on the concall. Dimer acid contributed close to INR 140 crores and isostearic acid contributed INR 26 crores. Management also indicated dimer acid is around 25% to 30% of revenue and isostearic acid around 5% to 6%. Linoleic acid was described as around 30% of revenue share, but the revenue number was not provided.

On geography, domestic sales contributed 91% of FY26 revenue, implying exports were about 9%. Export destinations highlighted in the presentation and/or concall include the US, Europe and Japan, along with other regions shown in the presentation’s market map.

Strategy and catalysts: utilisation, exports, and a pipeline of new products

Management’s near-term plan is built around four levers: cost optimisation, product upgradation, new products, and geographical diversification.

Capacity utilisation: management targets a step-up

Fairchem stated the plant capacity is 80,000 tonnes and current utilisation is around 65% to 66%. Management guided that FY27 utilisation could rise to 75% to 80%, and that the plant could exceed 95% utilisation in the next two years. The key assumption behind this outlook is that selling becomes viable as dumping pressure reduces.

Exports: from 8% to 10% toward about 20%

Management described multiple external tailwinds: lower tariffs with the US, potential free trade agreements with the UK and EU, and rupee depreciation. In the concall, management said commercial exports to the US have restarted on a small scale and meaningful volumes could resume within about six months. They also guided that exports could rise from about 8% to 10% to about 20%.

New products: bypass fat first, a novel-process oleochemical next

Two new product tracks were discussed:

First, bypass fat from PFAD. Management stated the plant would be put into operation next month and contribution could start slowly from Q3.

Second, a new oleochemical product based on an additional raw material and a novel process. Management said commissioning is expected by end of Q2, but meaningful revenue would take at least two to two-and-a-half years because of stabilisation, validation and customer approval cycles. Management also mentioned initial capex of about INR 20 to 25 crores and an initial capacity around 8,000 tonnes, with the longer-term ambition to scale to 40,000 tonnes over about five years.

Takeaways: a weak FY26, but clearer near-term levers

FY26 was a difficult year for Fairchem Organics, with revenue decline, margin compression, and stretched working capital. However, Q4 FY26 showed that margins can recover meaningfully when realizations improve, and management’s commentary suggests the pricing environment has become more supportive since late FY26.

The near-term investor lens is likely to focus on three measurable checkpoints that management itself put on the table: improvement in capacity utilisation toward 75% to 80% in FY27, export mix moving toward about 20%, and sustained EBITDA margins toward the 8% level that management said it is targeting. The longer-dated optionality rests on the new oleochemical project, where the timeline is explicitly multi-year and dependent on customer validations.